ReviewJournal of autoimmunity2015
The immunogenetics of Behçet's disease: A comprehensive review.
Review in Journal of autoimmunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 3 syntheses or guidelines pooled it, 195 citations in OpenAlex.
- Behçet's Disease: A Comprehensive Review on the Role ofInternational journal of molecular sciences · 2023Pooled it
- Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2020Pooled it
- Association between Interleukin-10 Gene Polymorphisms and Behcet's Disease Susceptibility: Evidence from a Meta-Analysis.Journal of immunology research · 2020Pooled it
- Analysis of receptor tyrosine kinase genetics identifies two novel risk loci in GAS6 and PROS1 in Behçet's disease.Scientific reports · 2016Trial
- Diabetes Mellitus Prevalence by Uveitis Etiology at a Japanese Tertiary Center.Diagnostics (Basel, Switzerland) · 2026Article
- Behçet's spectrum disorders: genetic and immunological insights into an emerging disease concept.World journal of pediatrics : WJP · 2026Review
- The Role of HLA-B Typing in Behçet's Disease and Spondyloarthritis: Genetic and Clinical Insights.Life (Basel, Switzerland) · 2026Article
- Hidradenitis suppurativa with systemic autoinflammatory features in patients of Moroccan origin: case report and implications for personalized medicine.Frontiers in immunology · 2026Article
- Genetic analysis of Behçet's disease using whole-exome sequencing and bioinformatics analysis in Korean patients.Frontiers in genetics · 2026Article
- Polyethylene glycol loxenatide reduces NETosis and immunofluorescence hyperactivation in Behçet's disease.European journal of medical research · 2025Article
- Unraveling the complexities of pediatric Behçet's disease clusters.World journal of pediatrics : WJP · 2025Article
- Predicting response to infliximab and interferon-α in Behçet's syndrome: An exploratory analysis from the BIO-BEHÇET'S randomized controlled trial.Rheumatology and immunology research · 2025Article
- Characterization of potential salivary biomarkers in Behçet's disease.Internal and emergency medicine · 2025Article
- Mucosal ulcers, extremity nodules, and fevers.JAAD case reports · 2025Article
- An immune-related adverse event of Behcet's-like syndrome following pembrolizumab treatment.BMC pulmonary medicine · 2024Article
- Association of IL-23R and IL-10 variations with Behçet disease: a genetic analysis study.Immunologic research · 2024Article
- Causal relationship between gut microbiota and Behçet's disease: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Oral Lesions as the Primary Manifestations of Behçet's Disease: The Importance of Interdisciplinary Diagnostics-A Case Report.Biomedicines · 2023Article
- Effects of breast milk on Behçet's disease clinical features.Turkish journal of medical sciences · 2023Article
- Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet's disease.Arthritis research & therapy · 2023Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Behçet's disease is a chronic multisystem inflammatory disorder characterized mainly by recurrent oral ulcers, ocular involvement, genital ulcers, and skin lesions, presenting with remissions and exacerbations. It is thought that both environmental and genetic factors contribute to its onset and development. Although the etiology of Behçet's disease remains unclear, recent immunogenetic findings are providing clues to its pathogenesis. In addition to the positive association of HLA-B*51, which was identified more than four decades ago, and which has since been confirmed in multiple populations, recent studies report additional independent associations in the major histocompatibility complex class I region. HLA-B*15, -B*27, -B*57, and -A*26 are independent risk factors for Behçet's disease, while HLA-B*49 and -A*03 are independent class I alleles that are protective for Behçet's disease. Genome-wide association studies have identified associations with genome-wide significance (P < 5 × 10(-8)) in the IL23R-IL12RB2, IL10, STAT4, CCR1-CCR3, KLRC4, ERAP1, TNFAIP3, and FUT2 loci. In addition, targeted next-generation sequencing has revealed the involvement of rare nonsynonymous variants of IL23R, TLR4, NOD2, and MEFV in Behçet's disease pathogenesis. Significant differences in gene function or mRNA expression associated with the risk alleles of the disease susceptibility loci suggest which genes in a disease-associated locus influence disease pathogenesis. These genes encompass both innate and adaptive immunity and confirm the importance of the predominant polarization towards helper T cell (Th) 1 versus Th2 cells, and the involvement of Th17 cells. In addition, epistasis observed between HLA-B*51 and the risk coding haplotype of the endoplasmic reticulum-associated protease, ERAP1, provides a clue that an HLA class I-peptide presentation-based mechanism contributes to this complex disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.